Cholecystokinin octapeptide (CCK-8) has been shown to be coupled to phosphoinositide turnover in pancreatic acini as well as in a kind of neuroblastoma cell and a human embryonic cell line. Little is known, however, about its link with phosphatidylinositol breakdown in the brain. The brains (minus cerebella) from 1-2-day-old neonatal rats were enzymically dissociated into single cells. The intact cells were prelabelled by incubation with myo-[3H]inositol for 3 h, and were then stimulated with agonists in the presence of 10 mM-LiCl. Carbachol at 1 mm induced an increase in InsP3 labelling in brain cells (peak at 30 min, and then a gradual decrease), and a static accumulation of InsP with time, whereas the labelling of InsP, remained essentially unchanged. A very similar time-response curve was obtained for 10 nM-CCK-8 in stimulating phosphoinositide turnover. The dose-response curve for incubated brain cells revealed that the formation of
INTRODUCTION
Cholecystokinin (CCK), which was originally discovered in the gastrointestinal tract, has been shown to be the major hormonal regulator of the pancreatic acinar cells. It is composed of a group of structurally related peptides, among which the Cterminal octapeptide (CCK-8) has all the known activities of this hormone group. It has been demonstrated that CCK exerts its effects in the pancreatic acini via receptor-mediated phosphodiesteratic breakdown ofphosphatidylinositol bisphosphate, producing two intracellular messengers, 1,2-diacylglycerol (DAG) and Ins(l ,4,5)P3, which are involved in protein kinase C activation and intracellular Ca2+ mobilization respectively (Berridge, 1985; Williamson et al., 1985; Willems et al., 1986) .
CCK-8 has recently been found to be abundantly and widely distributed in the central nervous system of many species as a neurotransmitter or neuromodulator (Vanderhaeghen et al., 1975; Beinfeld, 1983) . In fact, the absolute quantity of this hormone is greater in the central nervous system than in the entire gut (Rehfeld, 1978) . Binding sites for CCK have been characterized in brain tissues from various species (Barrett et al., 1989b; Gut et al., 1989; Hill et al., 1990; Hruby et al., 1990; Zelles et al., 1990) , and these binding sites are known to couple to nucleotide-regulatory proteins (G-proteins) (Wennogle et al., 1988) . To our knowledge, central CCK-recognition sites have not yet been proved to link to any second-messenger system in the brain, including the phosphoinositide system, although phosphoinositide metabolism has been shown to be affected by CCK in neuroblastoma cells (Barrett et al., 1989a) and an embryonic pituitary cell line (Lo & Hughes,, 1988 Single-cell preparation and prelabelling with I3Hlinositol
Methods for cell preparation were a modification of those of Ransom et al. (1977) and Muraoka & Takahashi (1989) . Brains (minus cerebella) were taken quickly from 1-2-day-old neonatal Wistar rats and washed in D1SGH solution (made up of 50 ml of 20 x concentrated Puck's Dl salt solution/l, 3 g of glucose/l, 7.5 g of sucrose/l and 10 mM-Hepes buffer, adjusted to 320-330 mosM, pH 7.3). After removal of meninges, the brains were minced into 2-4 mm3 small pieces, and digested with resuspended in modified Krebs-Ringer buffer (KRB; 108 mMNaCl, 4.7 mM-KCl, 24.8 mM-NaHCO3, 1.18 mM-KH2PO4, 1.18 mM-MgSO4, 0.75 mM-CaCl2, 10 mM-LiCI, 11 mM-glucose, adjusted to pH 7.4).
Measurement of inositol phosphates
The procedure was a modification of the method of Monsma et al. (Schoepp & Johnson, 1988; Ohmori & Kuriyama, 1989; Dyck, 1990; Monsma et al., 1990) . The total volume of reaction mixture was 500 ,ul in each plastic vial (5 ml capacity), containing (2-5) x 105 cells in modified KRB, 10 mM-LiCI and 50 ,ul of chemicals. After preincubation at 36.5°C for 10 min in a shaking water bath, the cells were stimulated by chemicals at different concentrations and time periods. The incubations were terminated by the addition of 1 ml of chloroform/methanol (1: 2, v/v), followed by shaking and putting into ice-cold water. Then 330 ,ul of chloroform and 330 ,1 of distiled water were added to each tube, which was then centrifuged at 3000 g for 25 min for phase separation. A 1.3 ml sample of the upper aqueous phase was removed and diluted to 6.3 ml before being applied to 1 ml Dowex columns (AGIX8; 200-400 mesh; formate form). The columns were washed with 7 ml of 5 mM-inositol to remove free [3H]inositol and then with 7 ml of 60 mM-ammonium formate/ 5 mM-sodium tetraborate to remove [3Hlglycerophospho- 
RESULTS
Effects of carbachol and CCK-8 on phosphoinositide tumnover With stimulation by I mM-carbachol, there was a 34% increase in InsP3 labelling in brain cells 10 min after stimulation, which reached a peak at 30 min (47 % increase), and then fell to the baseline level at 45 min. In the meantime, there was a constant accumulation of InsP, to reach a 48 % increase at 45 min after stimulation (Fig. 1) Devazepide in the concentration range 1-10 nM (P < 0.05); the effect declined when the concentration was further increased to 100 and 1000 nm (Fig. 4a) . In contrast, the CCK-B antagonist L365,260 showed a sustained suppression of InsP3 formation at concentrations above 0.1 nm, i.e. in the range 1-1000 nm (Fig. 4b ).
DISCUSSION
It is well known that CCK-receptor occupation activates phospholipase C via G-protein, leading to production of two second messengers, DAG and InsP3, in peripheral tissues such as the pancreas. Besides, in the human embryonic pituitary cell line Flow 9000 and in CHP212 neuroblastoma cells, CCK has been documented to stimulate phosphoinositide turnover (Lo & Hughes, 1987 Barrett et al., 1989a) . However, little is known about the post-receptor signal transduction of CCK-8 in the brain.
To study the influences of certain neurotransmitters or neuromodulators on the phosphoinositide turnover in brain, one could use brain slices or dissociated brain cells. In cerebral-cortical slices prelabelled with [3H]inositol, the muscarinic-receptor agonist carbachol was shown to cause rapid accumulation of [3H]phosphoinositide, a reaction effectively reversed by muscarinic-receptor blockade (Brown et al., 1984; Batty et al., 1985; Batty & Nahorski, 1989) . Enzymically dissociated neonatal-rat brain cells, which have been used in neuroscience research (Gonzales et al., 1985; Dildy & Leslie, 1989; Muraoka & Takahashi, 1989) , were used in the present study. We were able to demonstrate unequivocally that CCK-8 accelerated the turnover of phosphoinositide in a manner almost identical with that of carbachol. Whereas the labelling of InsP increased steadily with time, that of InsPJ reached a peak at 30 min and decreased thereafter. The latter may result from continuous hydrolysis of a limited amount of [3H]phosphatidylinositol bisphosphate available, and/or a decreased sensitivity to CCK-8 (as well as to carbachol) after prolonged receptor activation. It should be pointed out that the changes induced by carbachol observed in the present study are not as rapid and dramatic as were seen in brain-slice studies (Batty & Nahorski, 1989) , which may have been attributed to putative damage to the cell membrane by the enzyme trypsin.
A bell-shaped dose-response curve is very often seen in the pharmacology of CCK-8. An established phenomenon of CCK's effect in pain modulation is that it antagonizes the opiate effect at a low dose, and mimics the opioid effect at a high dose (Faris et al., 1983 ; R. G. . In the dose-response curve for CCK-8 stimulation of production of InsP3 in dissociated brain cells, we also see a bell-shaped curve with a peak at 10 nm and a clear-cut decrease at 1 /,M. The simplest explanation would be that a high-affinity site is responsible for the effect at low concentrations, whereas a low-affinity site is responsible for the opposite effect at high concentrations. Although we had no evidence to demonstrate the presence of high-and low-affinity sites in our experimental model, we did have means to analyse whether these two effects are mediated by two different types of CCK receptor, type A and type B. Using the specific CCK-A antagonist Devazepide and the CCK-B antagonist L365,260, we were able to construct the dose-response curves for the relevant antagonists to affect the production of [3H]InsP3 evoked by CCK-8 at 10 nm. It was interesting to show that both CCK-A and CCK-B antagonists worked at the same concentration (1 nM), although the CCK-B antagonist seemed to have a broader effective dose range (1-1000 nmol) as compared with the CCK-A antagonist (1-10 nM). Although the data were straightforward in their own right, they are difficult to reconcile with the existing information that in adult rat brain most of the CCK receptors are of the B type (Moran et al., 1986; D. R. Hill et al., 1987) .
Further experiments are needed to clarify this phenomenon: (a) a radioreceptor assay to see whether CCK-A and CCK-B receptors are equally abundant in the rat brain tissue at the neonatal stage of development; (b) a brain-slice study using adult rat brain to see whether the effect of CCK-8 could be preferentially blocked by CCK-B antagonist.
In conclusion, this is the first demonstration that in neonatalrat brain cells one of the post-receptor events of CCK-8 is to increase the production of InsP3. The potential importance of InsP3 in mediating the anti-opioid effect of CCK-8 in pain modulation can be derived from the two following established facts (1) that InsP3 accelerated the Ca2+ release from the intracellular Ca2+-storage pool, resulting in an increase in intracellular [Ca2l] , and (2) that a cardinal mechanism of the opiate effect was to decrease intracellular [Ca2+] via blockade of Ca2+ influx (MacDonald & Werz, 1986; Tort et al., 1989; Wang et al., 1989) . In connection with this, it should be pointed out that a decrease in the InsP3-stimulating effect at higher concentrations of CCK-8 in the experiment in vitro may have some relevance to the finding in vivo, where the anti-opioid effect of CCK-8 tended to diminish and shift to an opio-mimetic effect along with an increase in dosage.
